Epimmune to Merge With IDM in Stock Deal

Cancer vaccine developer Epimmune Inc. said it agreed to merge with IDM SA, a privately held French biopharmaceutical company, in an all-stock transaction. Under terms of the agreement, IDM shareholders will receive about 3.77 shares of Epimmune common stock for each IDM share held. After the merger, the company will have about 102 million shares outstanding, with Epimmune's current shareholders owning about 22 percent of the company and IDM's current shareholders owning about 78 percent.

Yahoo News (http://biz.yahoo.com/ap/050316/epimmune_idm_1.html)